ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2349

Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review

Xue Han1, Leticia Ferri 1, Grace Crocket 2, Sophie Yoon 3, Tracy Slanger 3 and Mir Sohail Fazeli 3, 1Bristol-Myers Squibb Company, Princeton, NJ, 2Bristol-Myers Squibb; Rutgers University, New York City, NY, 3Doctor Evidence, Santa Monica, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Epidemiology, interstitial lung disease and systematic review, Prognosis, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is the most common lung manifestation of RA and the 2nd leading cause of death in RA patients.1,2 The purpose of this literature review was to characterize the epidemiology, risk/prognostic factors, and treatment landscape of rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Methods: A systematic literature review was conducted by searching MEDLINE, Embase, and Cochrane CENTRAL (inception-Dec 26, 2018) supplemented by conference proceedings from ACR and EULAR, and US and European clinical trial registries (2016 to 2018). Randomized controlled trials (RCTs), non-randomized clinical trials, and observational studies that investigated therapies for adults with RA-ILD and reported efficacy and safety outcomes were included. This was supplemented by a comprehensive search using Doctor Evidence LLC’s proprietary search platform (DOC Search) containing MEDLINE, clinicaltrials.gov, WHO-ICTRP, EPAR, Daily Med, and RSS feeds, targeting the most relevant literature on the epidemiology and risk/prognostic factors associated with RA-ILD.

Results: The results of search and screening yielded 42 publications eligible for evidence synthesis; 22 studies reporting on the epidemiology and risk/prognostic factors and 20 studies (1 non-randomized clinical trial and 19 observational studies) on treatments for RA-ILD (Figure 1).
Unadjusted incidence of ILD in RA patients ranged from 1.3/1,000 person-years for interstitial pneumonia-type ILD to 5.0/1,000 person-years for “probable or definite ILD.” RA-ILD prevalence ranged widely from 1.8% to 67%. This variation is more likely attributable to the difference in sample sizes, definitions of ILD, and how ILD was diagnosed across the eligible studies. Comorbidities among patients with RA-ILD included ischemic heart disease (13%), congestive heart failure (8.5%), and diabetes (9.9%). Advanced age was the strongest predictor of developing ILD with pre-existing RA and poorer prognosis once RA-ILD was present. Male gender, RA disease duration, and anti-CCP/CCP2 positivity were also reported as important potential risk factors for ILD. Of the 6 studies that included RA drug treatments in their multivariate models assessing risk factors for ILD among RA patients, only one identified drug use (steroids) as an independent risk factor for developing ILD.
A variety of therapies were used across studies with some studies reporting classes of medication, while others were focused on specific combinations of individual therapies (Table 1). The included studies showed moderate to good effect for all therapies used in RA-ILD for DAS28, dyspnea, diffusing capacity for carbon monoxide, forced vital capacity (FVC), forced expiratory volume (FEV1), FEV1/FVC, and exacerbation of ILD. Few safety outcomes of interest were reported.

Conclusion: This review highlights epidemiology and potential risk factors (male gender, RA duration, and anti-CCP positivity) for ILD development in RA patients. Well-designed RCTs and meta-analyses are warranted to fully assess optimal treatment efficacy and safety of RA-ILD therapies.


Fig 1AB

Figure: 1A PRISMA diagram for review on treatments; 1B PRISMA diagram for review on epidemiology and risk/prognostic factors

Table 1: Breakdown of study count per intervention


Refs

References


Disclosure: X. Han, Bristol-Myers Squibb, 3, Bristol-Myers Squibb Company, 3; L. Ferri, Bristol-Myers Squibb, 1, 3, 4, Bristol-Myers Squibb Company, 1, 3; G. Crocket, Bristol-Myers Squibb, 9, Rutgers University, 3; S. Yoon, Doctor Evidence, 3; T. Slanger, Doctor Evidence, 3; M. Fazeli, Doctor Evidence, 3.

To cite this abstract in AMA style:

Han X, Ferri L, Crocket G, Yoon S, Slanger T, Fazeli M. Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/epidemiology-risk-prognostic-factors-and-treatment-landscape-in-rheumatoid-arthritis-associated-interstitial-lung-disease-a-systematic-literature-review/. Accessed May 30, 2023.
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-risk-prognostic-factors-and-treatment-landscape-in-rheumatoid-arthritis-associated-interstitial-lung-disease-a-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences